OrthoPediatrics (NASDAQ:KIDS) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

OrthoPediatrics (NASDAQ:KIDS) issued its earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02), FiscalAI reports. The company had revenue of $72.66 million during the quarter, compared to analyst estimates of $68.50 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.

OrthoPediatrics Trading Down 0.8%

NASDAQ KIDS traded down $0.20 on Tuesday, hitting $23.82. 372,144 shares of the stock were exchanged, compared to its average volume of 180,831. OrthoPediatrics has a 52-week low of $14.42 and a 52-week high of $26.74. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The company has a market capitalization of $621.94 million, a price-to-earnings ratio of -14.18 and a beta of 0.99. The company’s 50-day moving average price is $23.04 and its two-hundred day moving average price is $19.38.

Insider Activity

In other news, major shareholder Jennifer Pritzker sold 302,369 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the sale, the insider owned 6,201,764 shares in the company, valued at $130,299,061.64. This represents a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David Pelizzon sold 302,369 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the sale, the director directly owned 6,201,764 shares of the company’s stock, valued at approximately $130,299,061.64. This trade represents a 4.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 2,100,000 shares of company stock worth $46,747,931 over the last quarter. Corporate insiders own 32.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on KIDS shares. BTIG Research reaffirmed a “buy” rating and set a $29.00 target price on shares of OrthoPediatrics in a report on Monday, September 14th. Needham & Company LLC lifted their price target on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Truist Financial upgraded OrthoPediatrics to a “hold” rating in a report on Thursday, October 1st. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, OrthoPediatrics currently has a consensus rating of “Moderate Buy” and an average price target of $26.50.

OrthoPediatrics Company Profile

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.

Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.